Universität zu Köln

Useini, Dritan, Schlomicher, Markus, Beluli, Blerta, Christ, Hildegard, Ewais, Elias, Haldenwang, Peter, Patsalis, Polykarpos, Moustafine, Vadim, Bechtel, Matthias and Strauch, Justus (2021). Transapical-transcatheter aortic valve implantation using the Edwards SAPIEN 3 valve. J. Cardiovasc. Surg., 62 (6). S. 609 - 618. TURIN: EDIZIONI MINERVA MEDICA. ISSN 1827-191X

Full text not available from this repository.

Abstract

BACKGROUND: Scarcely any data has been published on the mid-term effect of transapical-transcatheter aortic valve implantation (TA-TAVI) using the Edwards SAPIEN 3 valve (S3; Edwards Lifesciences Corp., Irvine, CA, USA). We present mid-term clinical and echocardiographic outcomes after TA-TAVI utilizing S3. METHODS: Between 02/2014-06/2017, 122 elderly patients with severe aortic stenosis underwent TA-TAVI utilizing S3 at our institution. We conducted clinical and echocardiographic follow-up. The mean follow-up was 15 months. All end-point-related outcomes were adjudicated ac-cording to Valve Academic Research Consortium-2 definitions. RESULTS: The STS-score of the entire cohort was 6.26 +/- 4.6. More than one-third of the patients exhibited severe peripheral artery disease. The 30-d all-cause mortality, all-stroke rate, and myocardial infarction of the entire cohort were 4.1%, 1.6%, and 0.8% respectively. Median survival time of the entire cohort was 35 months. The cumulative mid-term myocardial infarction and stroke rate was 2.6% and 3.5%, respectively. The postoperative moderate/severe paravalvular leakage occurred in 1.6% of cases. At discharge, one-year and two-year postprocedure peak/mean gradients were 16.6 +/- 8.3/ 9 +/- 5.1 mmHg, 18 +/- 6.9/ 10 +/- 4.5 mmHg, and 22.2 +/- 5.4/ 12.8 +/- 4.6 mmHg, respectively. The rate of new pacemaker cases was 14.1%. Acute kidney injury network 2/3 appears, as an independent predictor of mortality. CONCLUSIONS: We observed very promising early and mid-term clinical outcomes with a high degree of device success and good hemody-namic performance after TA-TAVI using the S3 in the intermediate risk patient profile. (Cite this article as: Useini D, Schlomicher M, Beluli B, Christ H, Ewais E, Haldenwang P, et al. Transapical-transcatheter aortic valve implantation the Edwards SAPIEN 3 valve. J Cardiovasc DOI: 10.23736/S0021

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Useini, Dritan UNSPECIFIED UNSPECIFIED UNSPECIFIED Schlomicher, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED Beluli, Blerta UNSPECIFIED UNSPECIFIED UNSPECIFIED Christ, Hildegard UNSPECIFIED UNSPECIFIED UNSPECIFIED Ewais, Elias UNSPECIFIED UNSPECIFIED UNSPECIFIED Haldenwang, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Patsalis, Polykarpos UNSPECIFIED UNSPECIFIED UNSPECIFIED Moustafine, Vadim UNSPECIFIED UNSPECIFIED UNSPECIFIED Bechtel, Matthias UNSPECIFIED UNSPECIFIED UNSPECIFIED Strauch, Justus UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-579499
DOI:	10.23736/S0021-9509.21.11523-X
Journal or Publication Title:	J. Cardiovasc. Surg.
Volume:	62
Number:	6
Page Range:	S. 609 - 618
Date:	2021
Publisher:	EDIZIONI MINERVA MEDICA
Place of Publication:	TURIN
ISSN:	1827-191X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language HIGH-RISK; CLINICAL-OUTCOMES; REPLACEMENT; ACCESS; STENOSIS; REGISTRY; IMPACT; REGURGITATION; METAANALYSIS; GENERATION Multiple languages Cardiac & Cardiovascular Systems; Surgery; Peripheral Vascular Disease Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/57949